OOIR: Observatory of International Research

Papers

(The TQCC of Drug Metabolism and Pharmacokinetics is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Corrigendum to “Utility of Göttingen minipigs for the prediction of human pharmacokinetic profiles after intravenous drug administration” [Drug Metabol Pharmacokinet 41 (2021) 100408]	189
Effects of genetic polymorphisms of canine CYP2D15 on in vitro hepatic metabolism and in vivo pharmacokinetics of celecoxib, and the strategy for the accurate prediction of human pharmacokinetics	109
The spectrum of hepatic clearance models, from old to new	63
Monocarboxylate transporter 10: substrate-dependent mode of transport	25
Development of an in vitro metabolism approach of acrylamide covalent drugs for predicting metabolism and disposition in human	24
The mass balance recovery, absorption, metabolism, and excretion of [14C]-orvepitant in healthy male subjects after oral dosing: radiosynthesis of [14c]-orvepitant	22
Beyond non-human primates: Transgenics and PBPK models for predicting the human PK of protein therapeutics	17
Clinical studies on pharmacogenomics and DDIS involving drug transporters	15
Applications of model simulation in pharmacological fields and the problems of theoretical reliability	15
Formation of reactive metabolites of benzbromarone in humanized-liver mice	15
Development of a new assay system for bladder cancer using interactions between cytochromes P450 and serum	14
Prediction and validation of fetal exposure to dual BCRP/P-GP drug substrates using the proteomics informed efflux ratio-relative expression factor (ER-REF) approach and PBPK modeling and simulation	14
Dual kinetics of OATP2B1: Inhibitory potency and pH-dependence of OATP2B1 inhibitors	13
Lysosomal trapping measurement in multiple cell types using a high content imaging (HCI) system	12
Double Trap Interface: A novel gas interface for high throughput analysis of biomedical samples by AMS	12
In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition	12
Pharmacokinetics of ginsenosides and effect of the lactic acid bacteria on pharmacokinetics of ginsenosides in mice and human	11
Human liver chimeric mouse and trasngenic animals are useful tools for quantitatively predicting clearance and drug-drug interactions in human	11
Strategies for enhancing oral exposure of water-insoluble compounds	10
Mathematical modeling of affinity design goals for CIS-binding BI-specific antibody-based molecules	9
Physiologically based pharmacokinetic modeling to predict the clinical effect of azole antifungal agents as CYP3A inhibitors on azelnidipine pharmacokinetics	9
Enzyme induction fundamentals, assays, data interpretation and in vivo translation	9
Appreciation to Reviewers	9
Effect of linker-payload design on the PK of ADCS	9
Gene and Oligonucleotide Delivery	9

This is no longer just about liver: LC-MS proteomics for organ exposure brain/kidney/gut/skin/placenta	8
Effect of antibiotic-administration period on hepatic bile acid profile and expression of pharmacokinetic-related proteins in mouse liver, kidney, and brain capillaries	8
Pharmacokinetic interaction of caffeine and theophylline in mice	8
In vitro and in vivo interactions between nicotine and the cannabis terpene limonene	8
Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation	8
Disposition of E-selectin-targeting liposomes in tumor spheroids with a perfusable vascular network	7
Strategies for de-risking n-nitrosamine impurities in APIS	7
Suppression and induction of UGT by rhein and alvocidib in intestinal epithelial cells	7
Use of mathematical modeling to guide out-of-the-box thinking for ADC development	7
Lecture title not available	7
Cloning, sequence analysis, and tissue expression of marmoset paraoxonase 1	7
IN VITRO AND IN VIVO SYSTEMS FOR PREDICTING THE ADME OF PROTEIN THERAPEUTICS: ARE WE THERE YET?”	7
Clinical studies on pharmacogenomics and DDIS involving drug transporters	7
Effect of pregnancy-related hormones on mRNA expression of hepatic drug transporters and enzymes	6
Development of physiologically-based pharmacokinetic models to predict food effects and co-administration of proton pump inhibitors on the pharmacokinetics of sonidegib and vismodegib	6
Spatial mapping of gemcitabine and its pharmacologically active metabolites in tissues using MALDI mass spectrometry imaging	6
A workflow for oligonucleotide metabolite identification studies	6
Corrigendum to “Establishment of human intestinal organoids derived from commercially available cryopreserved intestinal epithelium and evaluation for pharmacokinetic study” [Drug Metabol Pharmacokine	6
Prediction of pharmacokinetics and pharmacodynamics in human for IRAK4 targeted protein degrader	6
Simple confirmation methods for rare but impaired variants of human flavin-containing monooxygenase 3 (FMO3) found in an updated genome resource databank	6
Exposure to mixed microplastic particles altered the fecal microbiome and its associated predictive functional pathways in mice	6
Micro-physiological system of human lung: The current status and application to drug discovery	6
Mechanisms of afatinib-induced intestinal epithelial barrier dysfunction using human mini-gut model	5
In vitro metabolic stability and in vivo phaarmacokinetic behavior of panobinostat in mouse models for the treatment of CNS tumors	5
Use of human liver microsomes to assess flavin-containing monooxygenase (FMO) metabolism in vitro	5
Therapeutic application of sequence-specific binding molecules for novel genome editing tools	5
Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6	5
Intestinal microbiota-mediated biotransformations alter the pharmacokinetics of the major metabolites of azathioprine in rats after oral administration	5
The effect of clofazimine in modulating intracellular concentrations of remdesivir and GS-441524: A potential mechanism of enhancing antiviral effects against SARS-COV-2	5
Interactions of sutezolid and its active metabolite with human transporters	5
Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery	5
Oligonucleotide delivery to antigen presenting cells by using schizophyllan	5
Metabolism of non-steroidal anti-inflammatory drugs (NSAIDs) by Streptomyces griseolus CYP105A1 and its variants	5
Experimental validation of the reliability of dilution method for plasma protein binding assay in human plasma using 12 commercial compounds	5
OCT1 transporter kinetics and long-term modulation studies in 3D cultured primary human hepatocytes	5
Development of fluorescent-labeled trapping reagents based on cysteine to detect soft and hard electrophilic reactive metabolites	5
Insights into drug development with quantitative systems pharmacology: A prospective case study of uncovering hyperkalemia risk in diabetic nephropathy with virtual clinical trials	5
Comparative analysis of microcystin toxicity in 2D and 3D cultured primary human hepatocytes	5
Epicatechin gallate and epigallocatechin gallate are potent inhibitors of human arylacetamide deacetylase	5
Effects of valproate, an HDAC inhibitor, on the expression of folate carriers and folate metabolism-related genes in the placenta of rats	5
Opportunities for microphysiological systems from the view of Japanese industries	5
Impact of donor diversity on phase I and phase II activities in cryopreserved human hepatocytes and human liver microsomes	5
Acetaminophen-induced liver injury and the microbiome	4
ADME: 14C-RLY-4008 following oral administration to rats	4
Stereoisomer separation of drugs and biomarkers using supercritical fluid chromatography to support PK/PD studies	4
Jasmone, an essential oil component, is an antagonist of aryl hydrocarbon receptor in liver and intestinal cells	4
Verification of a physiologically based pharmacokinetic model of caffeine that incorporates mechanistic descriptors of absorption	4
Beyond the basics: A deep dive into parameter estimation for advanced PBPK and QSP models	4
Evaluation of OSTΑ/Β transporter activity on the basal membrane of CACO-2 cell monolayers	4
Substrate-dependent characteristics in the transport function of SLC19A3: examination of the aspect of its sensitivity to flavonoids	4

Utility of Göttingen minipigs for the prediction of human pharmacokinetic profiles after intravenous drug administration	4
Unveiling the intracellular journey: GOLGA8N-mediated subcellular trafficking of siRNA drugs and its implications on silencing efficacy	4
Evaluating the impact of glycocalyx on partitioning and distribution of basic drugs	4
Increasing the therapeutic index of ADCs with payload binding selectivity enhancers	4
Comparison on metabolic fate of dendrobium polysaccharides in gut microbiota fermentation process between healty and diabetic status	4
Promiscuity and quantitative contribution of UGT2B17 in drug and steroid metabolism determined by experimental and computational approaches	4
Assessing complex drug-drug interactions using the truvivotm hepatocyte model	4
A practical approach for measuring acyl glucuronide migration half life	4
Understanding CYP3A4 and P-GP mediated drug-drug interactions through PBPK modeling - case example of pralsetinib	3
Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template	3
The effect of traditional herbal medicine on the permeability of clarithromycin and loxoprofen in CACO-2 cell model	3
【Continuous exposure to therapeutic drugs doxorubicin and vincristine reduces drug efficacy through transcriptional and post-transcriptional regulation of P-glycoprotein in follicular lymphoma】	3
The practical impact of the FDA draft guidance on human mass balance studies – a year of client discussions	3
Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources	3
Preclinical evaluation of the potential for cytochrome P450 inhibition and induction by tucatinib	3
Synthetic mRNA for ex vivo therapeutic applications	3
Functional assessment of immortalized human brain microvascular endothelial cells with different passage numbers: A case study for a prospective proposal on variability management of in vitro blood-br	3
Evaluation of a novel, primary human hepatocyte tri-culture model, truvivotm, for its ability to predict metabolic clearance of CYP, UGT, and AO substrates	3
What is the role of CYP1A1 in drug metabolism?	3
Species differences between rats and primates (humans and monkeys) in complex cleavage pathways of DS-8500a characterized by 14C-ADME studies in humans and monkeys after administration of two radiolab	3
Exploration of bioactivation of a branched-chain ketoacid dehydrogenase kinase (BDK) inhibitor	3
Clinical evaluation of [18F]pitavastatin for quantitative analysis of hepatobiliary transporter activity	3
Drug transporters are implicated in the diffusion of tacrolimus into the T lymphocyte in kidney and liver transplant recipients: Genetic, mRNA, protein expression, and functionality	3
Microbiome impacts on drug metabolism	2
Reduced theophylline clearance due to hepatic congestion secondary to right heart failure - A population pharmacokinetic study	2
Establishment and characterization of an in vitro model for NTCP substrate and inhibition assessment	2
Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs	2
OATP1B-mediated hepatic uptake of low-molecular weight acid compounds: assessment of HIF prolyl-hydroxylase inhibitors (DUSTATS)	2
Involvement of multiple cytochrome P450 isoenzymes in drug interactions between ritonavir and direct oral anticoagulants	2
Population pharmacokinetic modeling of treosulfan and rationale for dose recommendation in children treated for conditioning prior to allogeneic hematopoietic stem cell transplantation	2
Elucidate the metabolism of lipidated serotonin and selected drugs by cytochrome P450 2U1 (CYP2U1) in nanodiscs	2
Ferulic acid prevents Diosbulbin B-induced liver injury by inhibiting covalent modifications on proteins	2
Synthetic molecule libraries for nucleic acid delivery: Design parameters in cationic/ionizable lipids and polymers	2
P-GP limits rodent oral absoprtion of protacs	2
Adenovirus vector-based vaccine for infectious diseases	2
ADME considerations from FIH to drug approval	2
CYP and UGT inhibition to assess perpetrator drug-drug interaction potential	2
Pharmacokinetic properties of a truncated milk fat globule-EGF-like factor 8 in rats	2
Development and application of 3D cardiac tissues derived from human pluripotent stem cells	2
For hepatically cleared drugs, liver to blood KPUU at steady-state is always equal to FH , which exposes the deficiency of the present extended clearance concept equation	2
Imaging Mass Spectrometry (IMS) for drug discovery and development survey: Results on methods, applications and regulatory compliance	2
Transporter or membrane barriers effects on hepatic clearance (the extended clearance equation) models and the need for scaling for IVIVE	2